Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat
This article was originally published in The Pink Sheet Daily
Executive Summary
Cell Therapeutics to co-develop tosedostat, a potential non-cytotoxic oral therapy for acute myeloid leukemia, with U.K. biotech Chroma Therapeutics.
You may also be interested in...
Cell Therapeutics’ Tosedostat Gets Back On Track
FDA lifts clinical hold on first-in-class aminopeptidase inhibitor tosedostat, in investigator-sponsored Phase II trials for blood-related cancers as part of the company’s economic development strategy.
Cell Therapeutics’ Tosedostat Gets Back On Track
FDA lifts clinical hold on first-in-class aminopeptidase inhibitor tosedostat, in investigator-sponsored Phase II trials for blood-related cancers as part of the company’s economic development strategy.
Cell Therapeutics Should Consider Different Trial Design For Pixuvri, FDA's Pazdur Says
The odds were against Cell Therapeutics from the beginning of the Oncology Drugs Advisory Committee meeting, as FDA officials had concluded that the single, incomplete clinical trial did not provide enough evidence of efficacy.